title: Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.
abstract: Human papilloma viruses can induce warts, condylomas, and other intraepithelial cervical lesions that can progress to cancer. Cervical cancer is a serious problem in developing countries because early detection is difficult, and thus proper early treatment is many times missing. In this phase III clinical trial, we evaluated the potential use of MVA E2 recombinant vaccinia virus to treat intraepithelial lesions associated with papillomavirus infection. A total of 1176 female and 180 male patients with intraepithelial lesions were studied. They were injected with 10(7) MVA E2 virus particles directly into their uterus, urethra, vulva, or anus. Patients were monitored by colposcopy and cytology. Immune response was determined by measuring the antibody titer against MVA E2 virus and by analyzing the cytotoxic activity against cancer cells bearing papillomavirus DNA. Papillomavirus was determined by the Hybrid Capture method or by polymerase chain reaction analysis. By histology, 1051 (89.3%) female patients showed complete elimination of lesions after treatment with MVA E2. In 28 (2.4%) female patients, the lesion was reduced to CIN 1. Another 97 (8.3%) female patients presented isolated koilocytes after treatment. In men, all lesions were completely eliminated. All MVA E2-treated patients developed antibodies against the MVA E2 vaccine and generated a specific cytotoxic response against papilloma-transformed cells. Papillomavirus DNA was not detected after treatment in 83% of total patients treated. MVA E2 did not generate any apparent side effects. These data suggest that therapeutic vaccination with MVA E2 vaccine is an excellent candidate to stimulate the immune system and generate regression in intraepithelial lesions when applied locally.
authors.affiliation: 1 Virolab , S de RL de CV, CP 62130 Cuernavaca, Mexico .
authors.forename: Ricardo
authors.initials: R
authors.lastname: Rosales
authors.forename: Mario
authors.initials: M
authors.lastname: López-Contreras
authors.forename: Carlos
authors.initials: C
authors.lastname: Rosales
authors.forename: Jose-Roberto
authors.initials: JR
authors.lastname: Magallanes-Molina
authors.forename: Roberto
authors.initials: R
authors.lastname: Gonzalez-Vergara
authors.forename: Jose Martin
authors.initials: JM
authors.lastname: Arroyo-Cazarez
authors.forename: Antonio
authors.initials: A
authors.lastname: Ricardez-Arenas
authors.forename: Armando
authors.initials: A
authors.lastname: Del Follo-Valencia
authors.forename: Santiago
authors.initials: S
authors.lastname: Padilla-Arriaga
authors.forename: Miriam Veronica
authors.initials: MV
authors.lastname: Guerrero
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Pirez
authors.forename: Claudia
authors.initials: C
authors.lastname: Arellano-Fiore
authors.forename: Freddy
authors.initials: F
authors.lastname: Villarreal
mesh_terms: D000328:Adult; D000818:Animals; D001005:Anus Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D002642:Chick Embryo; D005260:Female; D015316:Genetic Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D027383:Papillomaviridae / Q000276:immunology / Q000472:pathogenicity; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000009:adverse effects; D002583:Uterine Cervical Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D019444:Vaccines, DNA; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: C560489:MVA vaccine; D053918:Papillomavirus Vaccines; D019444:Vaccines, DNA; D014765:Viral Vaccines